INTRODUCTION {#sec1-1}
============

Antimicrobials of plant origin have enormous therapeutic potential for various ailments.\[[@ref1][@ref2]\] They are effective in the treatment of infectious diseases and mitigate many of the side-effects that are often associated with synthetic antimicrobials. Natural products are evolutionary shaped molecules with a profound impact on human health.\[[@ref3]\] The World Health Organization (WHO) estimates that more than 80% of the world population is dependent (wholly or partially) on plant-based drugs.\[[@ref4]\] In East Africa, 90% of the population relies on traditional medicines (TM) and traditional health practitioners (THPs) as the primary source of healthcare.

Nature\'s biosynthetic engine produces innumerable secondary metabolites with distinct biological properties that make them valuable as health products or as structural templates for drug discovery. Aloes are reputed to have been used therapeutically since Roman times.\[[@ref5]\] The genus *Aloe* is common in Kenya, with about 60 taxa recognized.\[[@ref6]\] Because of unsustainable harvesting, trade in all species except *Aloe vera* is regulated by the Convention on the International Trade in Endangered Species of Wild Fauna and Flora (CITES).\[[@ref7]\] The latest review of some *Aloe* species shows that they have antibacterial, antifungal, anticancer, antiviral and immunomodulatory properties.\[[@ref8]\] From the survey, herbalists from the Lake Victoria region have traditionally used *Aloe secundiflora* to treat ailments including chest problems, polio, malaria and stomachache but with no knowledge of the scientific base of their activities.\[[@ref9]\]

The increasing prevalence of antibiotic resistance is a major health problem worldwide.\[[@ref10]\] The WHO and the European Commission (EC) have recognized the importance of studying the emergence and determinants of antimicrobial resistance and the need for strategies to control drug resistance.\[[@ref10][@ref11]\] Kenya has 2 million people living with HIV infections who may succumb to AIDS, which renders them susceptible to opportunistic infections.\[[@ref11]\] An increasing incidence of deaths due to tuberculosis (TB) and the known drawbacks of the current existing drugs including the emergence of multidrug-resistant strains have led to a renewed interest in the search for new anti-tubercular agents with novel modes of actions. Tuberculosis, which is a deadly infectious disease that annually kills about 3 million people worldwide,\[[@ref12]\] is now a highly associated infection of persons suffering from human immunodeficiency syndrome (HIS).

Other opportunistic infections, especially those associated with diarrhea are also increasingly fatal. The increasing resistance of *Escherichia coli* to ampicillin and trimethoprim sulfamethoxazole has been reported in many studies.\[[@ref10]\] This worldwide emergence of *E. coli, K. pneumoniae* and many other ί-lactamase producers has become a major therapeutic problem. Multidrug-resistant strains of *E. coli* and *K. pneumoniae* are widely distributed in hospitals through patient contact and are increasingly being isolated from community-acquired infections.\[[@ref13]\]

MATERIALS AND METHODS {#sec1-2}
=====================

Plant material collection, identification and extract preparation {#sec2-1}
-----------------------------------------------------------------

Mature fresh leaves of *Aloe secundiflora* Engl. were collected from Kisii central district, Kenya, in June 2008 based on the ethnobotanical survey that was carried out earlier.\[[@ref9]\] The plant was authenticated by a plant taxonomist (Mr. Karimi Lucas) from the Department of Pharmacy and Complementary Medicine, Kenyatta University, Nairobi, Kenya, in whose herbarium the voucher specimens are deposited. The leaves were chopped into small pieces, shade-dried and ground using a hammer-type milling machine (Meecan, CM/L-1364548, India). The powdered material was transferred into a 250 mL quick-fit round-bottomed flask and extracted in the soxhlet extractor using methanol for 72 h.\[[@ref14]\] The extract was filtered through a Whatmann filter paper No. 42 (125 mm) and concentrated using a rotary evaporator (Laborota 4000, SN 090816862, Germany) with the water bath set at 40°C,\[[@ref15]\] then dried under vacuum in a dessiccator over anhydrous CuSO~4~. The powdered residue was transferred into vials and stored at 4°C in airtight vials before analysis.

Test microorganisms {#sec2-2}
-------------------

The four mycobacterial strains used for the assays were *Mycobacterium tuberculosis, M. kansasii, M. smegmatis* and *M. fortuitum*, which were all obtained from the Center for Respiratory Diseases Research (CRDR), Kenya Medical Research Institute (KEMRI), Nairobi, Kenya. The common bacterial and fungal strains included *Salmonella typhi* (clinical isolate), *Klebsiella pneumoniae* (clinical isolate), *Pseudomonas aeruginosa* (ATCC 25852), *Escherichia coli* (ATCC 25922) *Staphylococcus aureus* (ATCC 20591) and *Candida albicans* (ATCC EK138), which were obtained from the Public Health Laboratories, Kenyatta National Hospital in Nairobi, Kenya.

Anti-tubercular assay using rapid non-radioactive BACTEC MGIT^™^ 960 system {#sec2-3}
---------------------------------------------------------------------------

The non-radioactive respiratory technique using the BACTEC MGIT^™^ 960 system (Beckon Dickinson diagnostic equipment, Sparks, Maryland, USA) was used for susceptibility testing against the mycobacterial strains.\[[@ref16]\] The extracts were dissolved in 0.01% dimethyl sulfoxide (DMSO) to final concentrations of 0.5, 1.0 and 2.0 mg mL^-1^. A stock solution of 2.0 mg mL^-1^ of the primary drug, isoniazid, was used as the positive control and 0.01% DMSO as the negative control, respectively. Into the 7 mL BBL^™^ MGIT^™^ tubes, 0.8 ml of the mixture containing OADC (supplement containing Oleic Acid, Bovine Albumin, Dextrose and Catalase added to provide essential substances for rapid growth of mycobacteria) and BBL^™^ MGIT^™^ PANTA (a mixture of antimicrobial agents that include Polymyxin B, Amphotericin B, Nalidixic Acid, Trimethoprim and Azlocillin) were added. Experiments were carried out in triplicate where BBL^™^ MGIT^™^ tubes with extract concentrations of 0.5, 1.0 and 2 mg mL-1 were inoculated with 500 μL of *Mycobacterium* sp. suspension. The strains included *M. tuberculosis* (Mtb), *M. kansasii* (Mk), *M. fortuitum* (Mf) and *M. smegmatis* (Ms). The BACTEC MGIT^™^ 960 system was loaded using manufacturer\'s instructions and incubated at 37°C. Culture vials which remained negative for a minimum of 42 days (maximum 56 days) were removed and recorded as negative, while growth units (GUs) for the positive ones were recorded appropriately.\[[@ref17]\] The same was done for the controls. Results were provided as positive/negative using a non-radiometric evaluation technique and numerical GUs recorded.\[[@ref17]\]

Evaluation of antibacterial and antifungal activity {#sec2-4}
---------------------------------------------------

The antibacterial and antifungal activities of the extract were assayed *in vitro* using agar disc diffusion (DD) method.\[[@ref18]\] Mueller Hinton agar and Potato Dextrose Agar (PDA) were prepared using manufacturer\'s instructions for purposes of culturing the bacteria and fungi respectively. Normal saline solution was used to dilute a 24-h culture of the bacterial type culture or clinical isolate to attain a 0.5 McFarland standard. Spread plate method was used to culture 100 μl of the microbial suspension that was introduced into the Petri dishes.\[[@ref19]\] Dry sterile discs (6 mm in diameter) were soaked in the plant extract (made by dissolving 300 mg of the extracts in 1000 μl of methanol, producing a homogenous orange solution), air-dried and placed on the spread plates at reasonable distances. Discs impregnated with methanol and air-dried were used as negative controls and various standard conventional antibiotics (Amoxicillin (Hangzhou Ruijian, China); Ciprofloxacin (Chengdu Ware Yuanheng, China); Fluconazole (Pfizer, UK)) as positive controls. The plates were then incubated at 35°C for 24 h. This was replicated three times for each pathogen.

*Candida albicans* was cultured by taking 100 μl from the broth and spreading on PDA. The culture was incubated at 25°C for 72 h. The cork boarer was used to pick a section of the young mycelium which was placed at the centre of the PDA plate and the dry discs which were impregnated with 100 μl of the plant extracts placed at a distance around the mycelium inoculum. The inoculum was incubated at 25°C for 72 h. Fluconazole and dry discs treated with methanol were also used as positive and negative controls respectively. All tests were performed in triplicate. Microbial growth inhibition was determined by measuring the zones of inhibition using a transparent ruler.

Minimum inhibitory concentration and minimum bactericidal/fungicidal concentration {#sec2-5}
----------------------------------------------------------------------------------

This was done only where the plant extract showed strong antibacterial activity by the DD method (≥9-15 mm).\[[@ref20]\] The wells were filled with 50 μl of the nutrient broth for bacterial strains and potato dextrose broth for *C. albicans*. The extract was then prepared by taking 300 mg of the plant extract and mixing with 1000 μl of DMF (0.01% Dimethyl formamide) for complete dissolution of the extract. Then 50 μl of the plant extract was dispensed into the first well before serial dilutions were done by transferring 50 μl of nutrient or potato dextrose broth containing the extract from the first well to the second well, and from the second well to the third well through the fourth well. Fifty microlitres (50 μl) of the test isolate were then dispensed into each well. One well (without extract or drug) was used as negative control whereas another well with 50 μl of the antibiotic (Amoxicillin /Ciprofloxacin/fluconazole) was used as positive control. Incubation was done at 37°C for 24 h.

The minimum inhibitory concentration (MIC) values were determined as the lowest concentrations of the extract that completely inhibited microbial growth. For the determination of minimum bactericidal/fungicidal concentration (MBC/MFC), wells where there was no growth were subcultured on nutrient agar and PDA. The lowest concentration of the plant extracts that did not yield any colony on the solid medium (Nutrient or PDA agar) after subculturing and incubating at 37°C for 24 h for bacterial strains and 25°C for 72 h for *C. albicans* was taken as the MFC/MBC.

Preliminary phytochemistry {#sec2-6}
--------------------------

The *Aloe secundiflora* Engl. extracts were subjected to preliminary phytochemical screening to determine the major chemical groups corresponding to active compounds responsible for the observed activity. For detection of tannins, saponins, alkaloids, cardiac glycosides, flavonoids and terpenoids, phytochemical screening was performed using standard procedures as described in Omwenga *et al*.\[[@ref16]\]

Data analysis {#sec2-7}
-------------

Data was analyzed using the Minitab Statistical Software 13.20, © 2000 Minitab Inc. PA 16801-9928, USA. Among the groups, significance test was performed using the one-way ANOVA at 95% significance level.

RESULTS {#sec1-3}
=======

[Table 1](#T1){ref-type="table"} shows the anti-tubercular (antimycobacterial) activity in varying concentrations of the methanol extract of *Aloe secundiflora* Engl. by BACTEC MGIT^™^ 960 system. The extract was found to be effective even at the lowest concentration (Zero GUs against all the mycobacteria strains, except *M. tuberculosis* which had 95 GUs). This was comparable to isoniazid (positive control) which gave Zero GUs at all concentrations. There was varied growth in DMF.

###### 

Antimycobacterial activity (GUs) of *Aloe secundiflora* Engl. using BACTEC MGIT^™^ 960 system

![](PR-3-95-g001)

The plant extract generally had strong antimicrobial activity \[[Figure 1](#F1){ref-type="fig"}\]. The zones of inhibition from the extracts were statistically significant (*P* ≤ 0.05). The zones of inhibition from the three treatments were statistically different except against *P. aeruginosa* where the activity of the plant extracts was not significantly different from the activity of the positive control (Amoxicillin) \[[Figure 1](#F1){ref-type="fig"}\]. The extract was more active (18.0 mm) than the positive control (amoxicillin) (17.33 mm) against *P. aeruginosa* \[[Table 2](#T2){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}\]. The extract was found be active against *S. typhi, S. aureus, E. coli* and *P. aeruginosa*, with zones of inhibition being ≥9.00 mm.

![Activity of *Aloe secundiflora* Engl. extract against various test microorganisms (*P*=0.05) Positive controls-Fluconazole for *C. albicans*, Zeftazidime for *S. typhi*, Ciprofloxacin for *K. pneumoniae* and Amoxicillin for *S. aureus, E. coli* and *P. aeruginosa*. Negative control-dried methanol discs](PR-3-95-g002){#F1}

###### 

Minimum inhibitory/ bactericidal concentrations (mg mL^-1^) of leaf extracts of *Aloe secundiflora* Engl
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DISCUSSION {#sec1-4}
==========

In the study, the activity of *Aloe secundiflora* Engl. extracts against mycobacterial strains showed that the plants contain pharmacologically active substances \[[Table 1](#T1){ref-type="table"}\]. The extract was active against all the mycobacterial strains used (Zero GUs against *M. kansasii, M. fortuitum* and *M. smegmatis* and 157 GUs against *M. tuberculosis* at the lowest concentration of 0.5 mgmL^-1^). For anti-ttuberculosis susceptibility tests, the MIC is considered as the lowest concentration inhibiting more than 99% of the initial bacterial concentration.\[[@ref1]\] The extract inhibited *M. tuberculosis* at 0.5 mg mL^-1^ by 99.159%. This means that *Aloe secundiflora* has compounds or groups of compounds that could prevent the growth and proliferation of mycobacteria.

Some flavonoids like catechins are well known for their antimicrobial properties against fungi, Gram-positive and Gram-negative bacteria.\[[@ref1][@ref21]\] The activity against tuberculosis strains could be due to the ability of flavonoids to form complexes with the bacterial cell wall, affecting cell-linked processes thereby inhibiting microbial growth.\[[@ref1][@ref22]\] They also inhibit several enzyme activities.\[[@ref22]\] The activity of *Aloe secundiflora* is in agreement with the report by Chakraborty and Chakraborti\[[@ref21]\] where catechins were said to have antibacterial activity by inhibiting the action of DNA polymerase.

Except for *K. pneumoniae* and *C. albicans*, general antibacterial results were also noted \[[Figure 1](#F1){ref-type="fig"}\]. The activity of extracts against various test microorganisms was statistically significant at P ≤ 0.05 \[[Figure 1](#F1){ref-type="fig"}\]. The activity of the test plant extracts against *P. aeruginosa* was comparable to that of amoxicillin (positive control). There was no significant difference in their activity. A zone of inhibition ≥9.00 mm is an indication of strong antimicrobial activity.\[[@ref20]\] Minimum inhibitory concentrations and MBCs produced by the extract against various bacterial test cultures showed strong antimicrobial activity \[[Table 2](#T2){ref-type="table"}\]. Good antimicrobial activity was shown against *E. coli* (MIC and MBC of 18.75 mg mL^-1^) and *P. aeruginosa* (MIC of 9.375 and MBC of 18.75 mg mL^-1^). The extract also gave good activity against *S. typhi* and *S. aureus* (with MICs and MBCs of 37.5 mg mL^-1^).

The extracts tested positive for tannins, terpenoids and flavonoids, and negative for saponins, cardiac glycosides and alkaloids. Activity against *S. aureus* and *E. coli* could be due to the presence of tannins. Tannins have been reported to be bacteriostatic or bactericidal against *S. aureus* and *E. coli*.\[[@ref23]\] The tannins could be disrupting the cell membranes of the microorganisms, hence their inhibitory activities. A study carried out by Waihenya *et al*.,\[[@ref8]\] revealed that *Aloe secundiflora* extract has been found to have a role in the control of fowl typhoid, indicating the possibility of the efficacy of *Aloe secundiflora* in other bacterial infections.

CONCLUSIONS {#sec1-5}
===========

The crude extracts of *Aloe secundiflora* Engl. could be useful in the development of new antimicrobial drugs, especially against infections caused by the four mycobacterial strains and against *P. aeruginosa*. Isolation of active principles, pharmacological and toxicological studies are currently underway and will be reported later. The study also supports the use of the plant by the local communities on the treatment of infections associated with the studied microorganisms, the results of which are promising.
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